• EOFlow announces two clinical study plans supported by Korean government

  • EOFlow has announced that the company will conduct two clinical studies in 2021, both supported by Korean government research grants.
    One study will be aiming at Type 2 diabetic people using the current wearable disposable insulin pump, EOPatch.  This study involves four university-hospitals and up to 120 Type 2 diabetic patients.
    The other study will be aiming at Type 1 diabetic people using EOFlow's first wearable closed-loop solution (automated insulin delivery), EOPatch X.  This study has 6 university-hospitals signed up and aims to conduct studies on up to 108 patients.  EOFlow has licensed TypeZero closed-loop algorithm which was adopted by at least one major durable pump company in the US and cleared the FDA for commercialization.

We use cookies. By continuing to use our site you accept our cookie policy. Find out more about our privacy policy here